

EXHIBIT B

Sills Cummis & Gross
A Professional Corporation

The Legal Center
One Riverfront Plaza
Newark, New Jersey 07102-5400
Tel: 973-643-7000
Fax: 973-643-6500

Jeffrey J. Greenbaum
Member
Direct Dial: (973) 643-5430
E-mail: jgreenbaum@sillscummis.com

101 Park Avenue
New York, NY 10112
Tel: 212-643-7000
Fax: 212-643-6500

**CONTAINS INFORMATION MARKED AS AEO/CONFIDENTIAL UNDER THE
DISCOVERY CONFIDENTIALITY ORDER**

September 26, 2024

VIA Email

Honorable Freda L. Wolfson, U.S.D.J.
Lowenstein Sandler LLP
One Lowenstein Drive
Roseland, NJ 07068

**Re: Opposition to SaveOnSP's September 16, 2024 Motion to Compel
Johnson & Johnson Health Care Systems Inc. v. Save On SP, LLC,
Civil Action No. 22-2632 (JKS) (CLW)**

Dear Judge Wolfson:

On behalf of JJHCS, we write to oppose SaveOnSP's September 16, 2024 motion to compel JJHCS to produce documents "sufficient to show" the instances in which it investigated, enforced, or "contemplated" enforcing the relevant CarePath terms and conditions. There is nothing for the Court to compel: JJHCS has already produced the documents showing what it did to investigate or enforce CarePath's terms and conditions, including enforcement against accumulators, maximizers, and SaveOnSP specifically. And discovery in this case has shown what JJHCS alleged from the beginning: SaveOnSP made it impossible for JJHCS to comprehensively and accurately "enforce" the CarePath terms by deploying an astonishing array of evasive and deceptive tactics, all designed to thwart JJHCS's ability to identify patients enrolled in the SaveOnSP program. And those efforts appear to continue to this day.

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 2

SaveOnSP may not like the story this evidence tells, but that is no basis for a motion to compel. As JJHCS has already made clear to SaveOnSP, there is no centralized repository in JJHCS's systems that houses yet more evidence of enforcement or "contemplated" enforcement. *See* SaveOnSP Ex. 28 (Sept. 11, 2024 Email from J. Long to E. Snow) at 2. The only other thing JJHCS could possibly do is run targeted searches over certain custodians' emails, simply to ensure that all bases are covered. JJHCS offered to do exactly that, but SaveOnSP refused the offer, unilaterally declared impasse, and filed this motion. The Court should therefore deny SaveOnSP's motion. And even if the Court were to grant it, the end result would be the same: as explained below, there are no documents for JJHCS to turn over that match the strawman SaveOnSP has concocted. To the extent that SaveOnSP wishes to better understand what enforcement steps JJHCS took and did not take and why, it is free to explore those topics at depositions.

DISCUSSION

I. SaveOnSP Intentionally Thwarted JJHCS's Enforcement Efforts at Every Turn

The premise of SaveOnSP's motion is there must be evidence in JJHCS's files demonstrating that the "no other offer" provision of CarePath's terms does not actually mean "no other offer." Specifically, SaveOnSP intimates that JJHCS had full knowledge of which patients were in the SaveOnSP program; "learned" that those patients were breaching their CarePath agreements; and nevertheless "accepted or acquiesced" to SaveOnSP helping itself to JJHCS's patient assistance money. Mot. at 2–3. This notion is closely related to SaveOnSP's theory (also the subject of ceaseless motion practice) that JJHCS was fully aware of SaveOnSP's misconduct for many years, yet decided not to mitigate its hundreds of millions of dollars in damages, ostensibly based on some mysterious calculus of net advantage.

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 3

These premises are false—an elaborate and absurd smokescreen designed to distract from SaveOnSP’s own misconduct. The truth is simple. SaveOnSP knew full well that its “SaveOnSP offering” violated the CarePath terms and conditions. But instead of abiding by those terms and leaving CarePath alone, SaveOnSP instead chose to take the money anyway, all the while covering its tracks through an elaborate campaign of deception. SaveOnSP was creative and relentless in its deceit:

- It [REDACTED];¹
- it [REDACTED];²
- its employees [REDACTED]
[REDACTED];³
- it [REDACTED]⁴

¹ See, e.g., Ex. 1 (Express Scripts 1350_00012745) [REDACTED]
[REDACTED]; Ex. 2 (SOSP 0775633) [REDACTED]
[REDACTED]; Ex. 3 (Express Scripts 1350_00015078) [REDACTED]
[REDACTED] Ex. 4
(Express Scripts 1350_00022531) ([REDACTED]
[REDACTED])

² Compare Ex. 5 (2022 SaveOnSP Drug List, available at https://hr.uky.edu/sites/default/files/Saveon%20Drug%20List%20July%202022_0.pdf (advising patients “your final cost will be \$0”), with Ex. 6 (2024 SaveOnSP Drug List, available at <https://www.saveonsp.com/wp-content/uploads/2023/10/AllOther012024.pdf> (advising patients “your final cost will be reduced”).

³ See Ex. 7 (Nov. 10, 2023 Dep. of Ayesha Zulqarnain) at 169:20–170:21, 185:2–186:5 ([REDACTED]
[REDACTED]; *id.* at 114:18–116:12, 149:8–23, and 179:7–17 ([REDACTED]); Ex. 8 (Apr. 24, 2024 Supplemental Interrogatory Responses) at 6–7 ([REDACTED]
[REDACTED]).

⁴ See Ex. 9 (SOSP_0346349) ([REDACTED]
[REDACTED]).

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 4

- it [REDACTED]
- it even [REDACTED]⁶

As a result of these efforts, JJHCS has lacked precise and reliable information about which individuals are enrolled in both CarePath and the SaveOnSP program. This is why, in June 2023, JJHCS sought leave of Court to share SaveOnSP’s “patient list”—produced in discovery but designated Attorneys Eyes Only—with certain relevant business personnel, so they could use it to mitigate damages and remove those patients from the CarePath program. In its moving papers, JJHCS explained that, without the patient list, “JJHCS personnel cannot independently determine who these patients are with the necessary certainty, because the SaveOnSP Program is designed precisely to evade detection.” Dkt. No. 109 at 3–4 (quoting Compl. ¶ 101). SaveOnSP vehemently objected. Judge Waldor denied JJHCS’s application.

Thus we arrive at an extraordinary position: SaveOnSP is now repeatedly before this Court insisting that JJHCS is not serious about wanting to enforce its terms and conditions; but at the very same time SaveOnSP is taking continuous steps both in the market and in this litigation to prevent JJHCS from doing just that. Even setting aside its marketplace efforts at evasion detailed above, if SaveOnSP truly believed JJHCS had made a deliberate decision not to remove SaveOnSP patients despite having comprehensive and reliable information about who they are, then it would have no objection to allowing JJHCS to use the SaveOnSP patient list to mitigate damages. That list would

⁵ Ex. 8 (Apr. 24, 2024 Supplemental Interrogatory Responses) at 6–7 ([REDACTED]).

⁶ See, e.g., Ex. 10 (SOSP_0297353) at 27 ([REDACTED]).

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 5

not be telling JJHCS anything it doesn't already know according to SaveOnSP's arguments. Yet SaveOnSP refuses to allow JJHCS to use the patient list and claims that permitting that would do SaveOnSP grievous economic harm. SaveOnSP has never explained this contradiction and will never be able to explain it. But absent an explanation, this Court should treat all of SaveOnSP's arguments on this topic—and its accompanying demands for endless documents designed to mire this case in discovery—with skepticism.

II. JJHCS Has Nevertheless Spent Enormous Time and Resources on Enforcement, and Has Already Produced the Documents Reflecting Those Efforts

JJHCS has produced countless documents—including those cited by SaveOnSP in other pending motions—[REDACTED]

[REDACTED] See Ex. 11 at 2 (JJHCS_00259893) ([REDACTED]
[REDACTED]; Ex. 12 at 10 (JJHCS_00139021) ([REDACTED]
[REDACTED]). SaveOnSP's own documents show it had reached the same conclusion. For example, in a November 2022 email [REDACTED]

[REDACTED] Ex. 13 (SOSP_1346903) at 1–2. [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] *Id.* at 2.

It is unsurprising, then, that JJHCS's enforcement documents largely focus on the same theme: how to identify whether patients are in compliance with CarePath's terms and conditions. Most of those efforts were straightforward. As shown in the roughly [REDACTED]
[REDACTED], [REDACTED]. See

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 6

SaveOnSP Ex. 5 (JJHCS_00205596) at -618-19 (“[REDACTED]”
[REDACTED]); *see also id.* at -619
 (“[REDACTED]”
[REDACTED]). SaveOnSP does not dispute that JJHCS produced these policies, [REDACTED]
[REDACTED] a. SaveOnSP Ex. 5; *see* Mot. at 4 n.3 ([REDACTED]
[REDACTED]). And these are precisely what Your Honor ordered JJHCS to produce, i.e., “documents
reflecting the company’s enforcement instructions and policy.” Dkt. No. 192 at 13.⁷

But JJHCS’s efforts were no match for SaveOnSP, the self-identified “[REDACTED]” Ex.
14 (SOSP_0399401). Nor could JJHCS simply ask impacted patients whether they were enrolled in
SaveOnSP because [REDACTED]
[REDACTED]. *See, e.g.*, Ex. 10 (SOSP_0297353) at 27 ([REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]); SOSP_0521205 ([REDACTED]
[REDACTED]).⁸ And, of course, SaveOnSP avoided honest interaction with JJHCS at all costs. *See supra*

⁷ SaveOnSP’s discussion of this ruling grossly mischaracterizes JJHCS’s previous argument to Your Honor. SaveOnSP claims JJHCS asserted “that it could have hundreds of thousands of documents about enforcing its eligibility criteria.” Mot. at 3 (citing Jan. 24, 2024 Tr. at 30–33). In fact, JJHCS correctly noted that the search terms demanded by SaveOnSP yielded hundreds of thousands of hits—a point SaveOnSP itself conceded. *See* Dkt. No. 180 at 11 (SaveOnSP insisting that it would not be burdensome for JJHCS to review 188,000 more documents).

⁸ Because of the format and file size of this native call recording, JJHCS has not included it as an exhibit, but has identified it by Bates number so that SaveOnSP is able to review the cited material. If Your Honor wishes to review the audio file, JJHCS will be happy to provide it through an FTP transfer or to arrange for a transcription.

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 7

n.3; Ex. 15 (SOSP_2124758) (“[REDACTED]
[REDACTED]”).

Still, JJHCS redoubled its efforts. It hired vendors and developed additional policies to attempt to identify relevant patients, including those enrolled in the SaveOnSP program. (And it produced documents detailing those efforts long ago).⁹ Consider, for example, just one of these documents, [REDACTED]

[REDACTED]. Ex. 18 (JJHCS_00076059). [REDACTED]
[REDACTED]
[REDACTED] *Id.* at -064. [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]. *Id.*

Moreover, [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] *Id.* at -066. The [REDACTED]
[REDACTED]
[REDACTED]. *Id.* at -069. [REDACTED]

⁹ *E.g.*, Ex. 16 (JJHCS_00002382) (“[REDACTED]
[REDACTED]”); Ex. 17 (JJHCS_00004439) [REDACTED]”); Ex. 18 (JJHCS_00076059) [REDACTED]”); Ex. 19 (JJHCS_00190425) [REDACTED]
Ex. 20 (JJHCS_00276832) [REDACTED]
[REDACTED]).

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 8

[REDACTED]
[REDACTED]
[REDACTED] at -070. Later
produced documents show [REDACTED]

[REDACTED]. Ex. 19 (JJHCS_00190425) (“[REDACTED]
[REDACTED]”); Ex. 20 (JJHCS_00276832) [REDACTED]
[REDACTED]; Ex. 21 (JJHCS_00276859) [REDACTED]
[REDACTED].

JJHCS also has produced data—[REDACTED]
[REDACTED] *E.g.*, Ex. 22 (JJHCS_00139016); *see also* Ex. 23 (JJHCS_00139017). For
example, JJHCS_00139016 lists, [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] Ex. 22 (JJHCS_00139016). [REDACTED]

[REDACTED] *Id.* These same documents also

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]. Ex. 22 (JJHCS_00139016) ([REDACTED]
[REDACTED]); *see also* Ex. 23 (JJHCS_00139017) ([REDACTED]
[REDACTED]).

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 9

Additionally, [REDACTED]

[REDACTED]
See Ex. 24 (TRIALCARD_00009752) ([REDACTED]); Ex. 25
(TRIALCARD_00009753) ([REDACTED]). [REDACTED]
[REDACTED]

[REDACTED] See, e.g., Ex. 24 (TRIALCARD_00009752) at Rows 11, 12. [REDACTED]
[REDACTED]. E.g., Ex.
Id. at Row 2; Ex. 25 (TRIALCARD_00009753) at Row 3 ([REDACTED]
[REDACTED]). And, at SaveOnSP's request, JJHCS has asked a second
vendor, RIS Rx, to produce final records of all benefits investigations that it performed during the
relevant time period. Ex. 26 (Aug. 23, 2024 Ltr. from J. Long to M. Nussbaum). SaveOnSP has also
independently pursued discovery from TrialCard and RIS Rx through subpoenas and other motions.

Finally, while JJHCS's enforcement efforts continue in the market, including through new
revisions to its terms and conditions, JJHCS has offered to produce discovery relating to those efforts,
too. For example, JJHCS has agreed to produce updated enforcement policies related to its new terms
and conditions implemented in 2024, which expressly and by name preclude patients from being in
SaveOnSP. See SaveOnSP Ex. 28 at 3; see Ex. 27 ([REDACTED]
[REDACTED]

[REDACTED] The parties are currently
negotiating the mutual exchange of additional documents relating to these 2024 terms and conditions.
Ex. 28 (Sept. 23, 2024 Ltr. from J. Long to T. Stone) at 1–2.

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 10

III. There Is Nothing for the Court to Compel

This is not the first time this issue has been before the Court. Your Honor already has ruled on a near identical motion from SaveOnSP in its February 6, 2024 Order, holding that “to strike the proper balance and considering proportionality, it is appropriate for Plaintiff to search for, and produce, documents reflecting the company’s enforcement instructions and policy, during the entirety of the agreed upon discovery time frame (April 2016-November 2023), concerning eligibility criteria set forth in the [May-Not-Use] provision.” Dkt. No. 192 at 13. JJHCS has complied with this ruling to the letter. But beyond that, JJHCS has also produced a vast swathe of documents reflecting its enforcement efforts, including those relating to CAPm, CAPa, benefits investigations, and dealings with vendors like TrialCard and RIS Rx.

That is in large part why—even though this case is about SaveOnSP’s secret scheme about which JJHCS knew little—SaveOnSP has produced from only 31 document custodians, while JJHCS has 45 (and SaveOnSP is seeking another 24 custodians, which would take the total to 69). This runs afoul of any measure of reasonableness or proportionality—especially when the Court considers that SaveOnSP’s whole business scheme and course of conduct in this litigation has been about making comprehensive and accurate enforcement of terms and conditions close to impossible. SaveOnSP is, of course, free to use any of the documents discussed above at depositions or at trial to better understand what policy decisions JJHCS was pursuing and why, or to try and advance its theory of the case. But it should not be heard to complain that JJHCS is hiding the evidence of its enforcement efforts. The documents sufficient to show those efforts have already been produced.

Nor is there any merit to SaveOnSP’s nebulous demand that JJHCS produce documents showing “contemplated” enforcement efforts. *See* Mot. at 1. As Your Honor has repeatedly

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 11

admonished SaveOnSP, what matters is not what JJHCS may have “contemplated” but rather what JJHCS actually did. *See, e.g.*, Dkt. No. 192 at 19 (“What matters for purposes of liability and damages are not the changes that Plaintiff contemplated implementing, but actual changes that occurred.”); *see also* Dkt. No. 264 at 5 (denying SaveOnSP’s motion for reconsideration and reiterating that “to mount its mitigation defense . . . Defendant does not require communications as to why Plaintiff or J&J did not make certain decisions or vice versa; rather, it will need evidence as to actual changes that occurred”). And, again, JJHCS has already produced evidence of what it did to enforce its terms.

In any event, it is unclear how JJHCS could satisfy SaveOnSP’s demands for “contemplated” enforcement efforts. Tellingly, SaveOnSP itself omits any proposed type of document or search parameters from its moving papers. This is unsurprising. For months, JJHCS repeatedly offered to confer with SaveOnSP in an attempt to resolve this dispute. And for months, SaveOnSP rebuffed all of JJHCS’s efforts to discuss these issues.¹⁰ Even after SaveOnSP finally took JJHCS up on its offer to confer, it neither clarified what it sought nor what categories of documents JJHCS could produce to resolve the dispute. Instead, SaveOnSP doubled down, insisting that JJHCS either produce this nebulous category of documents or “stipulate that [JJHCS] (1) never enforced the ‘other offer’ provision as to patients on accumulators, maximizers, or SaveOn-advised plans; *and* (2) never enforced any portion of the provision that states ‘may not be used with any other coupon, discount, prescription savings card, free trial or other offer.’” SaveOnSP Ex. 15 at 2 (emphasis supplied). This is a non-starter because JJHCS does not agree. Again, SaveOnSP is entitled to ask any remaining

¹⁰ *See* SaveOnSP Ex. 12 at 3 (“JJHCS remains willing to confer with SaveOnSP on this issue on June 18, 2024, despite SaveOnSP’s failure to accept JJHCS’s three prior offers to do so.”); SaveOnSP Ex. 6 (“JJHCS again offers to meet and confer with SaveOnSP, as we have offered to do on several occasions.”).

Honorable Freda L. Wolfson, U.S.D.J.
September 26, 2024
Page 12

questions it has at depositions and to use JJHCS's documents to support its positions at trial. But SaveOnSP obviously cannot demand that JJHCS "stipulate" to SaveOnSP's own warped view of the facts.

The most that JJHCS could do to resolve this motion is what it repeatedly offered to do: run supplemental custodial searches to make doubly certain that the record on this issue is complete. SaveOnSP Ex. 28 at 3. In light of SaveOnSP's unwillingness to accept this compromise, JJHCS respectfully requests that the Court deny SaveOnSP's motion.

We appreciate Your Honor's attention to this matter.

Respectfully submitted,

/s/ Jeffrey J. Greenbaum

JEFFREY J. GREENBAUM

cc: All counsel of record

Exhibitu 1/4''
Eqphk gp vkcn' Hkngf ''
Wpf gt 'Ugc n

Exhibit 5

State Benchmark = All States except CA, CO, UT 2022 SaveOnSP Drug List

Please call 1-800-683-1074 to participate. Once enrolled, your responsibility will be \$0.



Effective July 1, 2022

The specialty medications included on the SaveOnSP Drug List are specific to your plan's prescription drug benefit and subject to change at any time. Prescription drug benefit plan terms will always take precedence. Medications with prior authorization criteria must be approved in advance by the plan and follow applicable laws and/or regulations. The specialty medications included on this list will have a 30% coinsurance, but with participation in SaveOnSP, **your final cost will be \$0**. Fill your specialty medications through your approved specialty pharmacy.

A

Abraxane

Actemra

Acthar

Adakveo

Adcetris

Adcirca

Advate

Adynovate

Afinitor

Afstyla

Aldurazyme

Alecensa

AlphaNine

Alprolix

Alunbrig

Ampyra

Arcalyst

Asceniv

Aubagio

Austedo

Avastin

Avonex

Avsola

B

Benefix

Benlysta

Beovu

Berinert

Blenrep

Bosulif

Braftovi

Brukinsa

C

Cabliivi

Cabometyx

Calquence

Carbaglu

Cayston

Cerdelga

Cholbam

Cibinquo

Cimzia

Cinryze

Copaxone

Cosentyx

Crysvita

Cuvitru

Cyramza

Cystadrops

D

Darzalex

Darzalex Faspro

Dojolvi

Doptelet

Dupixent

E

Elaprase

Elelyso

Eloctate

Empliciti

Enbrel

Enhertu

Enjaymo

Entyvio

Erbix

Erivedge

Erleada

Esperoct

Evenity

Evkeeza

Exjade

Exkivity

Exondys 51

Extavia

Eylea

F

Fabrazyme

Farydak

Fasenra

Feiba NF

Ferriprox

Fintepla

Firazyf

Firdapse

Folotyf

Forteo

Fotivda

Fulphila

G

Galafold

Gamifant

Gammagard

Gattex

Gazyva

Gilenya

Gilotrif

Givlaari

Glatiramer Acetate

Glatopa

Gleevec

Gocovri

Granix

H

Haegarda

Hemlibra

Herceptin

Herceptin Hylecta

Herzuma

Hetlioz

Humate-P

Humira

Hyqvia

I

Ibrance

Iclusig

Idelvion

Ilumya

Imcivree

Imfinzi

Increlex

Inflectra

Ingrezza

Inlyta

Inqovi

Inrebic

Istodax

Ixempra

Ixinity

J

Jadenu

Jakafi

Jemperli

Jevtana

Jivi

Juxtapid

Jynarque

K

Kadcyla

Kalbitor

Kalydeco

Kanjinti

Kanuma

Kesimpta

Keveyis

Kevzara

Kisqali

Kisqali Femara Co-Pack

Kogenate FS

Koselugo

Kovaltry

Krystexxa

Kuvan

L

Lenvima

Letairis

Leukine

Libtayo

Livmarli

Lonsurf

Lorbrena

Lucentis

Lumakras

Lumizyme

Lumoxiti

Lupkynis

Luxturna

Lynparza

M

Makena

Margenza

Mayzent

Mekinist

Mektovi

Mvasi

Myalept

N

Nerlynx

Neulasta

Neupogen

Nexavar

Nexviazyme

Ninlaro

Nityr

Nivestym

Northera

Novoeight

Novoseven RT

Nplate

Nubeqa

Nucala

Nulibry

Nuplazid

Nuwiq

Nyvepria

O

Ocaliva

Ocrevus

Ogivri

Olumiant

Ontruzant

Onureg

Opdivo

Opsumit



Orencia
Orenitram
Orfadin
Orgovyx
Orkambi
Orladeyo
Otezla
Oxbryta
Oxervate
Oxlumo

P

Padcev
Palynziq
Pemazyre
Perjeta
Phesgo
Piqray
Plegridy
Polivy
Poteligeo
Procysbi
Promacta
Pulmozyme

Q

Qinlock

R

Radicava
Ravicti
Rebif
Rebinyn
Recombinate
Remicade
Renflexis
Retevmo
Revatio
Revcovi
Riabni
Rinvoq
Rituxan
Rituxan Hycela
Rixubis
Ruxience
Rybrevant
Rydapt

S

Sandostatin Lar
Depot
Saphnelo
sapropterin
Sarclisa
Scemblix
Serostim
Signifor
Signifor LAR

Siliq
Skyrizi
Skytrofa
Soliris
Somatuline Depot
Somavert
Spinraza
Sprycel
Stelara
Stivarga
Strensiq
Sublocade
Susvimo
Sutent

T

Tafinlar
Tagrisso
Takhzyro
Taltz
Talzenna
Tasigna
Tavalisse
Tavneos
Tazverik
Tecentriq
Tecfidera
Tegsedi
Tepmetko
Thiola
Tivdak
Tobi
Tracleer
Trazimera
Tremfya
treprostinil
Tretten
Trikafta
Triptodur
Trodelvy
Truseltiq
Truxima
Tukysa
Turalio
Tykerb
Tysabri
Tyvaso

U

Udenyca
Ultomiris

V

Valchlor
Vectibix
Venclexta
Verzenio

Viltepso
Vistogard
Vonvendi
Votrient
Voxzogo
Vumerity
Vyleesi
Vyndamax
Vyndaqel
Vyondys 53
Vyxeos

W

Wakix
Welireg
Wilate

X

Xalkori
Xeljanz
Xembify
Xenazine
Xermelo
Xgeva
Xolair
Xospata
Xpovio
Xtandi
Xynthia
Xyrem

Y

Yervoy

Z

Zarxio
Zejula
Zelboraf
Zeposia
Ziextenzo
Zirabev
Zokinvy
Zolgensma
Zynlonta
Zytiga

Exhibit 6

State Benchmark = All States except CA, CO, UT 2024 Copay Assistance Benefit Drug List

Effective January 1, 2024

Please call 1-800-683-1074 to participate. Once you've completed the manufacturer copay assistance program's enrollment process and consented to SaveOnSP monitoring your pharmacy account, your responsibility will be reduced.

The specialty medications included in the copay assistance benefit drug list are specific to your plan's prescription drug benefit and subject to change at any time. Prescription drug benefit plan terms will always take precedence. Medications with prior authorization criteria must be approved in advance by the plan and follow applicable laws and/or regulations. The specialty medications included on this list will have a 30 percent coinsurance, which may be subject to change. By completing the manufacturer copay assistance program's enrollment process and consenting to SaveOnSP monitoring your pharmacy account, **your final cost will be reduced**. Specialty medications will be filled through your approved specialty pharmacy.

A

Abraxane

Abrilada

Actemra

Adakveo

Adalimumab-adaz

Adbry

Adcetris

Adcirca

Advate

Adynovate

Afinitor

Afstyla

Aldurazyme

Alecensa

AlphaNine

Alprolix

Altuviio

Alunbrig

Amjevita

Ampyra

Amvuttra

Arcalyst

Asceniv

Aubagio

Austedo

Avastin

Avonex

Avsola

B

Bavencio

Benefix

Benlysta

Beovu

Berinert

Bivigam

Bosulif

Braftovi

Briumvi

Brukinsa

C

Cablivi

Cabometyx

Calquence

Camzyos

Carbaglu

Cayston

Cerdelga

Cerezyme

Cholbam

Cibinco

Cimerli

Cimzia

Cinryze

Columvi

Copaxone

Cortrophin

Cosentyx

Crysvisa

Cutaquig

Cuvitru

Cyltezo

Cyramza

Cystadrops

D

Daybue

Dojolvi

Doptelet

Dupixent

Durysta

E

Elahere

Elaprase

Elelyso

Elfabrio

Eloctate

Empaveli

Empliciti

Enbrel

Enhertu

Enjaymo

Entyvio

Epkinly

Erbitux

Erivedge

Erleada

Esbriet

Esperoct

Evenity

Evkeeza

Exjade

Exondys 51

Extavia

Eylea

F

Fabrazyme

Fasenra

Feiba NF

Ferriprox

Filspari

Fintepla

Firazyr

Firdapse

Folotyn

Forteo

Fotivda

Fulphila

Fylnetra

G

GalaFold

Gamifant

Gammagard

Gattex

Gazyva

Gilenya

Gilotrif

Givlaari

Glatiramer Acetate

Glatopa

Gleevec

Gocovri

Granix

H

Haegarda

Hemlibra

Herceptin

Herceptin Hylecta

Herzuma

Hetlioz

Humate-P

Humira

Hyqvia

Hyrimoz

I

Ibrance

Iclusig

Idelvion

Ilaris

Ilumya

Imcivree

Imfinzi

Increlex

Inflectra

Ingrezza

Inlyta

Inqovi

Inrebic

Istodax

Ixempra

Ixinity

J

Jadenu

Jakafi

Jaypirca

Jemperli

Jevtana

Jivi	Neupogen	Qinlock	Symdeko
Joenja	Nexavar	R	Synagis
Juxtapid	Nexvazyme	Radicava	T
Jynarque	Ninlaro	Ravicti	Tabrecta
K	Nityr	Rebif	Tafinlar
Kadcyla	Nivestym	Rebinyn	Tagrisso
Kalbitor	Northera	Recombinate	Takhzyro
Kalydeco	Novoeight	Releuko	Taltz
Kanjinti	Novoseven RT	Remicade	Talzenna
Kanuma	Nplate	Renflexis	Targretin
Kesimpta	Nubeqa	Retevmo	Tasigna
Keveyis	Nucala	Revatio	Tavalisse
Kevzara	Nulibry	Revcovi	Tavneos
Kineret	Nuplazid	Revlimid	Tazverik
Kisqali	Nuwiq	Rezlidhia	Tecentriq
Kisqali Femara Co-Pack	Nyvepria	Riabni	Tecfidera
Kitabis	O	Rinvoq	Tegsedi
Kogenate FS	Ocaliva	Rituxan	Tepezza
Koselugo	Ocrevus	Rituxan Hycela	Tepmetko
Kovaltry	Odomzo	Rixubis	teriparatide
Krazati	Ogivri	Rolvedon	Thiola
Krystexxa	Olumiant	Rubraca	Tibsovo
Kuvan	Ontruzant	Ruxience	Tivdak
Kyprolis	Onureg	Rybrevant	Tobi
L	Opdivo	Rydapt	Tracleer
Lamzedo	Opdualag	Rystiggo	Trazimera
Lenvima	Orencia	S	Tremfya
Leqembi	Orenitram	Sandostatin Lar Depot	treprostinil
Letairis	Orfadin	Saphnelo	Tretten
Leukine	Orgovyx	Sarclisa	Trikafta
Libtayo	Orkambi	Scemblix	Triptodur
Livmarli	Orladeyo	Serostim	Trodelyv
Lonsurf	Orserdu	Sevenfact	Truseltiq
Lorbrena	Otezla	Signifor	Truxima
Lucentis	Oxbryta	Signifor LAR	Tukysa
Lumakras	Oxervate	Siliq	Tykerb
Lumizyme	Oxlumo	Skyclarys	Tymlos
Lumryz	P	Skyrizi	Tysabri
Lunsumio	Padcev	Skysona	Tyvaso
Lupkynis	Palynziq	Skytrofa	Tzield
Luxturna	Pemazyre	sodium oxybate	U
Lynparza	Perjeta	Soliris	Udenyca
M	Phesgo	Somatuline Depot	Ultomiris
Makena	Piqray	Somavert	V
Margenza	Plegridy	Sotyktu	Vabysmo
Mayzent	Polivy	Spinraza	Valchlor
Mekinist	Ponvory	Sprycel	Vanflyta
Mektovi	Poteligeo	Stelara	Vectibix
Mvasi	Procysbi	Stivarga	Venclexta
Myalept	Promacta	Strensiq	Verzenio
N	Pulmozyme	Sublocade	Vioice
Nerlynx	Pyrukynd	Susvimo	Viltepso
Neulasta	Q	Sutent	Vistogard
	Qalsody	Syfovre	Vivitrol

Vonjo
Vonvendi
Votrient
Vowst
Voxzogo
Vpriv
Vumerity
Vyjuvek
Vyleesi
Vyndamax
Vyndaqel
Vyondys 53
Vyxeos

W

Wakix
Welireg
Wilate

X

Xalkori
Xeljanz
Xembify
Xenazine
Xenpozyme
Xermelo
Xgeva

Xolair
Xospata
Xpovio
Xtandi
Xyntha
Xyrem

Y

Yervoy
Yonsa
Yusimry

Z

Zarxio

Zejula
Zelboraf
Zeposia
Ziextenzo
Zirabev
Zokinvy
Zolgensma
Ztalmy
Zynlonta
Zynteglo
Zynyz
Zytiga

Exhibit 7''

Eqphk gpvkcn'Hkngf ''

Wpf gt 'Ugc n

Exhibit 8

E. Evans Wohlforth, Jr.
ROBINSON & COLE LLP
666 Third Avenue, 20th Floor
New York, NY 10174
212-451-2954
ewohlforth@rc.com

Philippe Z. Selendy (*admitted pro hac vice*)
Andrew R. Dunlap (*admitted pro hac vice*)
Meredith Nelson (*admitted pro hac vice*)
Elizabeth Snow (*admitted pro hac vice*)
SELENDY GAY PLLC
1290 Avenue of the Americas
New York, NY 10104
212-390-9000
pselendy@selendygay.com
adunlap@selendygay.com
mnelson@selendygay.com
esnow@selendygay.com

Attorneys for Defendant Save On SP, LLC

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

JOHNSON & JOHNSON HEALTH CARE
SYSTEMS INC.,

Plaintiff,

v.

SAVE ON SP, LLC,

Defendant.

Civil Action No. 22-2632 (JKS) (CLW)

**DEFENDANT'S SUPPLEMENTAL
RESPONSES AND OBJECTIONS TO
PLAINTIFF'S INTERROGATORIES**

To: Jeffrey J. Greenbaum, Esq.
SILLS CUMMIS & GROSS, P.C.
One Riverfront Plaza
Newark, New Jersey 07102
973-643-7000

Adeel A. Mangi, Esq.
Harry Sandick, Esq.
George LoBiondo, Esq.
PATTERSON BELKNAP WEBB
& TYLER LLP
1133 Avenue of the Americas
New York, New York

*Attorneys for Plaintiff Johnson & Johnson
Health Care Systems Inc.*

Pursuant to Federal Rules of Civil Procedure 26 and 33, and Local Civil Rule 33.1, Defendant Save On SP, LLC (“SaveOnSP”), by and through its undersigned counsel, hereby supplements its Responses and Objections to Plaintiff Johnson & Johnson Health Care Systems Inc.’s (“JJHCS”) Interrogatory Nos. 2, 17, 18 and 20, contained in SaveOnSP’s previously-served Responses and Objections. These responses should be deemed to supplement and amend SaveOnSP’s disclosures under Rule 26(a) of the Federal Rules of Civil Procedure. If SaveOnSP learns that in some material respect its responses are incomplete or incorrect, SaveOnSP will supplement or correct them if the additional or corrective information has not otherwise been made known to JJHCS during the discovery process or in writing. Fed. R. Civ. P. 26(e)(1)(A). SaveOnSP’s responses to these Interrogatories are based on information available to it at the time it made them. SaveOnSP reserves the right to modify or supplement its responses.

GENERAL OBJECTIONS

1. JJHCS does not limit any of its Interrogatories to nonprivileged material. SaveOnSP objects to each Interrogatory to the extent that it seeks a disclosure of information which is subject to the attorney-client privilege, the work product doctrine, the common-interest privilege, or any other applicable privileges, immunities, or doctrines.

2. JJHCS does not limit any of its Interrogatories to information withing SaveOnSP's possession, custody, or control. SaveOnSP objects to each Interrogatory to the extent that it seeks disclosure of information that is not within SaveOnSP's possession, custody, or control that SaveOnSP can locate after a reasonable inquiry.

OBJECTIONS TO DEFINITIONS

3. SaveOnSP objects to the definition of "SaveOnSP" as including attorneys and accountants who may be outside of SaveOnSP's possession, custody, and control. SaveOnSP interprets the term "SaveOnSP" to mean SaveOnSP, LLC, and any and all predecessors and successors in interest, assignees, parents, subsidiaries, affiliates, divisions or departments, agents, representatives, directors, officers, employees, committees, and all persons or entities acting or purporting to act on behalf or under the control of SaveOnSP, LLC.

4. SaveOnSP objects to the definition of "SaveOnSP Program," as described in Complaint ¶¶ 9-17, because it mischaracterizes SaveOnSP's services. SaveOnSP will not use this definition.

5. SaveOnSP objects to the definition of "You" and "Your" to the same extent that it objects to the definition of "SaveOnSP."

6. SaveOnSP objects to the term "or other substance" in the definition of "Pharmaceutical Manufacturer" as vague and ambiguous. SaveOnSP will interpret the term "Pharmaceutical Manufacturer" to mean any entity that develops, produces, manufactures, creates, licenses, or distributes any pharmaceutical, drug, or medicine used in the treatment, cure, prevention or diagnosis of any illness, disease, disorder, or other condition.

Dated: April 24, 2023

By: /s/ E. Evans Wohlforth, Jr.
E. Evans Wohlforth, Jr.
ROBINSON & COLE LLP

666 Third Avenue, 20th Floor
New York, NY 10174
212-451-2954
ewohlforth@rc.com

Philippe Z. Selendy
Andrew R. Dunlap
Meredith Nelson
Elizabeth Snow
SELENDY GAY PLLC
1290 Avenue of the Americas
New York, NY 10104
212-390-9000
pselendy@selendygay.com
adunlap@selendygay.com
mnelson@selendygay.com
esnow@selendygay.com

Attorneys for Defendant Save On SP, LLC

**SUPPLEMENTAL RESPONSES TO PLAINTIFF'S INTERROGATORY NOS. 2, 17, 18,
AND 20**

INTERROGATORY NO. 2:

Describe, in as much detail as possible, Your involvement in the creation and use of the presentation found at <https://vimeo.com/513414094> (hereinafter, SaveOnSP IPBC Video) as discussed in the Complaint (see, e.g., Compl. ¶¶ 9–11, 53–56).

RESPONSE:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

SaveOnSP designates its response to this Interrogatory as Confidential under the Discovery Confidentiality Order, so-ordered November 22, 2022, ECF No. 62.

INTERROGATORY NO. 17:

Describe, in as much detail as possible, all measures that You have utilized to prevent any Pharmaceutical Manufacturer or manufacturers from being able to identify Your employees or representatives as being affiliated with SaveOnSP, or to make it more difficult for them to do so.

RESPONSE:

A series of horizontal black bars of varying lengths, some starting from the left edge and others indented, creating a rhythmic, abstract pattern. The bars are arranged in a vertical sequence, with some appearing as single strokes and others as part of a larger, more complex arrangement. The overall effect is one of dynamic movement and visual rhythm.

A series of horizontal black bars of varying lengths, representing redacted text. The bars are arranged in a list-like fashion, with some bars starting at the left margin and others indented. The lengths vary significantly, with some bars spanning most of the page width and others being much shorter. The bars are solid black and have uniform thickness.

SaveOnSP designates its response to this Interrogatory as Attorneys' Eyes Only under the Discovery Confidentiality Order, so-ordered November 22, 2022, ECF No. 62.

INTERROGATORY NO. 18:

Describe, in as much detail as possible, all measures that You have utilized to prevent Your current or former employees from communicating with JJHCS or others with regard to Save-OnSP's conduct at issue in this lawsuit, or to make it more difficult for them to do so.

RESPONSE:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[illegible]

SaveOnSP designates its response to this Interrogatory as Confidential under the Discovery Confidentiality Order, so-ordered November, 22, 2022, ECF No. 62.

INTERROGATORY NO. 20:

Describe, in as much detail as possible, each instance where and all circumstances under which You have instructed Your representatives or employees to lie to, mislead, or deceive Pharmaceutical Manufacturers including with regard to their affiliation with SaveOnSP.

RESPONSE:

9

SaveOnSP designates its response to this Interrogatory as Attorneys' Eyes Only under the Discovery Confidentiality Order, so-ordered November 22, 2022, ECF No. 62.

CERTIFICATION OF SAVE ON SP, LLC

I, Jody Miller, am the President of Save On SP, LLC ("SaveOnSP"). I am authorized to submit this certification on behalf of SaveOnSP. I certify that the foregoing answers made by me to these Interrogatories are true. I am aware that if any of the foregoing answers are willfully false, SaveOnSP and I are subject to punishment. I certify that in responding to the foregoing Interrogatories, I have furnished all information available to SaveOnSP, its agents, employees and attorneys. As to those answers which are not within my personal knowledge, I certify that I have provided the name and address of every person from whom such information was received or, where the source of such information is documentary, a full description of the document including its location.

Save On SP, LLC

By: 

Jody Miller
President

Date: April 23, 2024

Exhibitu 9/25''
Eqphk gpvcn'Hkngf ''
Wpf gt 'Ugc n

Exhibit 26



August 23, 2024

Julia Long
(212) 336-2878

VIA EMAIL

Matthew Nussbaum
Selendy Gay, PLLC
1290 Avenue of the Americas
New York, NY 10104

Re: Possession, Custody, and Control of RIS RX's Documents
Johnson & Johnson Health Care Systems, Inc. v. Save On SP, LLC,
2:23-cv-02632 (JKS) (CLW)

Dear Matthew:

We write in response to SaveOnSP's August 13, 2024 letter and further to our letter of August 6, 2024 regarding whether JJHCS has possession, custody, or control of documents held by RIS RX.

In our prior correspondence, we explained that under the November 2022 Master Services Agreement between JJHCS and RIS RX (the "MSA"), [REDACTED]

[REDACTED] MSA § 16.1. Based on that carve-out, as well as the issues in the litigation, we asked SaveOnSP to clarify, with specificity, which documents and communications that SaveOnSP seeks. In your August 13, 2024 letter, SaveOnSP refused to do so, repeating the demand for "all documents and communications 'with respect to' the relevant Benefits Investigations within RIS [RX]'s possession," including but not limited to "communications between J&J and RIS concerning RIS's services, as well as RIS's internal communications regarding its work on behalf of J&J (not including records and information created as part of RIS's 'business processes' as defined in [REDACTED] August 13, 2024 Ltr. from M. Nussbaum to J. Long at 1.

SaveOnSP's demands are untethered from the Federal Rules of Civil Procedure. As you know, Rule 26 disfavors "unreasonably cumulative or duplicative" discovery. Fed. R. Civ. P. 26(b)(2)(C)(i). There is simply no reason that RIS RX need provide JJHCS with copies of documents already in JJHCS's possession and which are plainly available through party discovery. JJHCS therefore will not request that RIS RX provide it with "communications between J&J and RIS concerning RIS's services," as demanded. August 13, 2024 Ltr. from M. Nussbaum to J. Long at 1.

Matthew Nussbaum, Esq.
August 23, 2024
Page 2

Nonetheless, in the interest of compromise, JJHCS has asked RIS RX to provide JJHCS with its internal documents and communications concerning RIS RX's efforts to identify whether patients taking Janssen drugs were also a member of a SaveOn-advised plan during the time period April 1, 2016 to November 7, 2023. We are currently negotiating appropriate search parameters for such a collection with RIS RX.

As to our responses and objections to Request No. 58,¹ as you know, in the nine months since JJHCS served its November 20, 2023 responses and objections to SaveOnSP's Fourth Set of RFPs, Request No. 58 has been the subject of extensive correspondence between the parties. To be clear, in response to Request No. 58, JJHCS previously agreed to "ask TrialCard, Inc. to produce all benefits investigation reports from the Time Period that reflect inquiries about whether a patient taking Stelara or Tremfya is enrolled in an accumulator or maximizer program (including SaveOnSP), to the extent such documents exist and can be located after a reasonable search" but that JJHCS would not otherwise search for or produce documents responsive to these Requests. See Nov. 20, 2023 R&Os to SaveOnSP's Fourth Set of RFPs at 6-8. TrialCard has made that production. In your August 13 letter, you ask whether JJHCS "is aware of responsive BIs conducted for it by another company besides TrialCard or RIS [RX]." Aug. 13, 2024 Ltr. from M. Nussbaum to J. Long at 2. JJHCS is not aware of any other benefits investigations that "identified or attempted to identify whether a Person enrolled in CarePath was or could be a member of a health plan advised by SaveOnSP." SaveOnSP's Fourth Set of RFPs, dated Oct. 20, 2023, at 10.

Please let us know if you have any questions or would like to discuss further.

Very truly yours,

/s/ Julia Long

Julia Long

¹ Request No. 58 seeks "All documents or communications related to Benefits Investigations undertaken by JJHCS or any JJHCS Hub Entity that identified or attempted to identify whether a Person enrolled in CarePath was or could be a member of a health plan advised by SaveOnSP." SaveOnSP's Fourth Set of RFPs, dated Oct. 20, 2023, at 10.

Exhibit 27''

Eqphk gpvkcn'Hkngf ''

Wpf gt 'Ugc n

Exhibit 28



September 23, 2024

Julia Long
(212) 336-2878

VIA EMAIL

Taylor Stone, Esq.
Selendy Gay PLLC
1290 Avenue of the Americas
New York, NY 10104

Re: *Johnson & Johnson Health Care Systems, Inc. v. Save On SP, LLC*
No. 2:22-cv-02632 (JKS) (CLW)

Dear Taylor:

We write in response to SaveOnSP's August 23, 2024 letter and its email of September 10, 2024, and further to JJHCS's August 28, 2024 letter concerning SaveOnSP's Eleventh Set of Requests for Production.

Request No. 102 seeks "[a]ll Documents and Communications regarding the decision to adopt, adoption of, drafting of, or implementation of the New Terms," with "New Terms" defined as certain specified "terms in the CarePath terms and conditions for the Affected Drugs set forth in Appendices 1–3 to Plaintiff's Fourth Set of Interrogatories." In response, JJHCS has stated that it "is willing to meet and confer on appropriate, and reciprocal, search parameters concerning the New Terms." Sept. 23, 2024 Responses and Objections to SaveOnSP's 11th Set of RFPs at 6.

As you know, SaveOnSP initially took the position that the New Terms were irrelevant to both JJHCS's claims and SaveOnSP's mitigation defense. *See* Aug. 27, 2024 Supplemental Responses and Objections to JJHCS's 4th Set of Interrogatories at 5; Aug. 1, 2024 Email from J. Long to M. Nussbaum (memorializing the Aug. 1 conferral); *see also* Aug. 2, 2024 Email from M. Nelson to J. Long ("SaveOn's position is that J&J has not asserted any claims based on the 2024 terms and conditions and that Interrogatory No. 21 is therefore irrelevant to J&J's existing claims."). It was only after SaveOnSP served Request No. 102 that SaveOnSP stated that "the information sought in these requests is relevant to [SaveOnSP's] mitigation defense." Sept. 10, 2024 Email from T. Stone to J. Long. But SaveOnSP's position is inconsistent. SaveOnSP cannot claim a "mitigation defense" for a period during which it claims JJHCS is not accruing damages.

JJHCS's position on the New Terms is clear: they are part and parcel of the Complaint and the Proposed Amended Complaint. Accordingly, JJHCS proposes that the parties

Taylor Stone, Esq.
September 23, 2024
Page 2

meet and confer on appropriately tailored search parameters in response to SaveOnSP's Request No. 102 and a refresh, through to the same date, of SaveOnSP's production of documents in response to JJHCS's Request No. 23, which seeks "[a]ll documents and communications relating to . . . the terms and conditions of CarePath." *See* SaveOnSP's Nov. 23, 2022 R&Os to JJHCS's First and Second Set of RFPs at 22. By September 30, 2024 please advise whether SaveOnSP is prepared to refresh its production of documents in response to this request.

We reserve all rights and are available to meet and confer.

Very truly yours,

/s/ Julia Long
Julia Long